Prula-Cel Pivotal Trial Eyed for H2 2026 After Q2 FDA Meeting; Q1 Loss Narrows
summarizeSummary
Adicet Bio announced significant progress for its lead drug candidate, prula-cel, including an anticipated FDA meeting in Q2 2026 to discuss pivotal trial design for lupus nephritis/SLE, with a potential pivotal trial startup in the second half of 2026. The company also expects a mid-2026 Phase 1 update for prula-cel. While the reported narrower Q1 net loss was previously disclosed in SEC filings and news on May 13th, the detailed timeline for prula-cel's regulatory and clinical advancement is new and highly material. For a clinical-stage biotech with a modest market capitalization, these developments provide a clearer, accelerated path towards commercialization and represent a significant de-risking event for its pipeline. This news is likely to serve as a major catalyst for the stock. Investors will now focus on the outcomes of the upcoming FDA meeting and further updates on the pivotal trial initiation.
At the time of this announcement, ACET was trading at $8.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.4M. The 52-week trading range was $6.01 to $17.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.